JP5410432B2 - プロテインキナーゼ阻害剤としてのピリミジン誘導体 - Google Patents

プロテインキナーゼ阻害剤としてのピリミジン誘導体 Download PDF

Info

Publication number
JP5410432B2
JP5410432B2 JP2010526364A JP2010526364A JP5410432B2 JP 5410432 B2 JP5410432 B2 JP 5410432B2 JP 2010526364 A JP2010526364 A JP 2010526364A JP 2010526364 A JP2010526364 A JP 2010526364A JP 5410432 B2 JP5410432 B2 JP 5410432B2
Authority
JP
Japan
Prior art keywords
compound
methyl
cyclopentyl
pyrimido
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010526364A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540509A5 (enExample
JP2010540509A (ja
Inventor
ジョナサン ジェイムス ホリック
スチュアート ドナルド ジョーンズ
クレア ジューン フリン
マイケル ジョージ トーマス
Original Assignee
サイクラセル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0719038A external-priority patent/GB0719038D0/en
Priority claimed from GB0806844A external-priority patent/GB0806844D0/en
Application filed by サイクラセル リミテッド filed Critical サイクラセル リミテッド
Publication of JP2010540509A publication Critical patent/JP2010540509A/ja
Publication of JP2010540509A5 publication Critical patent/JP2010540509A5/ja
Application granted granted Critical
Publication of JP5410432B2 publication Critical patent/JP5410432B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2010526364A 2007-09-28 2008-09-29 プロテインキナーゼ阻害剤としてのピリミジン誘導体 Active JP5410432B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0719038A GB0719038D0 (en) 2007-09-28 2007-09-28 Compound
GB0719038.2 2007-09-28
GB0806844.7 2008-04-15
GB0806844A GB0806844D0 (en) 2008-04-15 2008-04-15 Compound
PCT/GB2008/003305 WO2009040556A1 (en) 2007-09-28 2008-09-29 Pyrimidine derivatives as protein kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013230231A Division JP5863196B2 (ja) 2007-09-28 2013-11-06 プロテインキナーゼ阻害剤としてのピリミジン誘導体

Publications (3)

Publication Number Publication Date
JP2010540509A JP2010540509A (ja) 2010-12-24
JP2010540509A5 JP2010540509A5 (enExample) 2011-10-06
JP5410432B2 true JP5410432B2 (ja) 2014-02-05

Family

ID=40199600

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010526364A Active JP5410432B2 (ja) 2007-09-28 2008-09-29 プロテインキナーゼ阻害剤としてのピリミジン誘導体
JP2013230231A Expired - Fee Related JP5863196B2 (ja) 2007-09-28 2013-11-06 プロテインキナーゼ阻害剤としてのピリミジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013230231A Expired - Fee Related JP5863196B2 (ja) 2007-09-28 2013-11-06 プロテインキナーゼ阻害剤としてのピリミジン誘導体

Country Status (9)

Country Link
US (3) US8563542B2 (enExample)
EP (2) EP2610256B1 (enExample)
JP (2) JP5410432B2 (enExample)
CN (1) CN101878216B (enExample)
CA (1) CA2700979C (enExample)
ES (2) ES2457394T3 (enExample)
PL (2) PL2610256T3 (enExample)
RU (2) RU2478100C2 (enExample)
WO (1) WO2009040556A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014076994A (ja) * 2007-09-28 2014-05-01 Cyclacel Ltd プロテインキナーゼ阻害剤としてのピリミジン誘導体

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007215221C1 (en) 2006-02-14 2013-05-30 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
CA2695753A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
US20110201818A1 (en) 2007-09-25 2011-08-18 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
MX346186B (es) 2008-06-23 2017-03-10 Vertex Pharma Inhibidores de proteina cinasas.
MX2011000021A (es) 2008-06-23 2011-02-24 Vertex Pharma Inhibidores de proteina cinasas.
DK2442809T3 (en) 2009-06-17 2016-12-19 Vertex Pharma Inhibitors of the replication of influenza virus
SG179206A1 (en) 2009-09-25 2012-04-27 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
NZ599342A (en) 2009-09-25 2014-04-30 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
US8354420B2 (en) 2010-06-04 2013-01-15 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 inhibitors
SI2638031T1 (en) 2010-11-10 2018-02-28 Genentech, Inc. Pyrazole aminopyrimidine derivatives as LRRK2 modulators
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
GB201205752D0 (en) * 2012-03-30 2012-05-16 Cyclacel Ltd Treatment
EP3670515B1 (en) 2013-03-15 2024-03-06 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
WO2015013635A2 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
EP3068776B1 (en) 2013-11-13 2019-05-29 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
RS57541B1 (sr) 2013-11-13 2018-10-31 Vertex Pharma Postupci za pripremu inhibitora replikacije virusa gripa
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
EP3099677A4 (en) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
KR101517414B1 (ko) * 2014-04-24 2015-05-04 고려대학교 산학협력단 염증성 질환의 예방 또는 치료용 약학 조성물
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
ES2764178T3 (es) 2014-12-16 2020-06-02 Kayla Therapeutics Dinucleótidos cíclicos fluorados para inducción de citocinas
MA42422A (fr) 2015-05-13 2018-05-23 Vertex Pharma Inhibiteurs de la réplication des virus de la grippe
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
PE20181287A1 (es) 2015-09-11 2018-08-07 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas
UA123946C2 (uk) 2015-09-11 2021-06-30 Дана-Фарбер Кенсер Інстітьют, Інк. Ацетамідтієнотриазолодіазепіни й шляхи їх застосування
US10738016B2 (en) 2015-10-13 2020-08-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. BRD4-kinase inhibitors as cancer therapeutics
CA3003288A1 (en) 2015-11-25 2017-06-01 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibitors and uses thereof
EP3424929A4 (en) * 2016-03-04 2019-08-07 Anhui New Star Pharmaceutical Development Co., Ltd PYRIMIDIN COMPOUNDS WITH SEVEN ELEMENTS, METHOD OF MANUFACTURING THEREOF, PHARMACEUTICAL COMPOSITION AND USES THEREOF
US11155556B2 (en) * 2016-04-07 2021-10-26 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
SG11202004009TA (en) * 2017-11-02 2020-05-28 Calico Life Sciences Llc Modulators of the integrated stress pathway
CA3145286A1 (en) * 2019-08-16 2021-02-25 Benjamin Skead Crystalline forms of pyrimidino diazepine derivative
WO2021032958A1 (en) 2019-08-16 2021-02-25 Cyclacel Limited Process for the preparation of a pyrimidino-diazepine derivative
EP4034132B1 (en) 2019-09-27 2026-02-25 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases
CN119365489A (zh) 2022-04-08 2025-01-24 印希比生物科学有限公司 Dr5激动剂与plk1抑制剂或cdk抑制剂组合疗法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9117635D0 (en) 1991-08-15 1991-10-02 British Telecomm Phase shifter
GB0302220D0 (en) 2003-01-30 2003-03-05 Cyclacel Ltd Use
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
CA2517020C (en) 2003-02-26 2012-06-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, method for the production and use thereof in the form of drugs
WO2005117944A2 (en) 2004-05-26 2005-12-15 The Texas A & M University System Hsp20 inhibits amyloidogenesis and neurotoxicity
EP1799684B1 (en) * 2004-10-04 2014-12-03 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
MX2007015905A (es) 2005-06-24 2008-03-06 Lilly Co Eli Derivados de tetrahidrocarbazol utiles como moduladores de receptor de androgeno (sarm).
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
AU2007215221C1 (en) 2006-02-14 2013-05-30 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
JP5087640B2 (ja) * 2007-03-22 2012-12-05 武田薬品工業株式会社 Ｐｌｋ１阻害剤として有用な置換ピリミドジアゼピン
US20110201818A1 (en) * 2007-09-25 2011-08-18 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
US8563542B2 (en) 2007-09-28 2013-10-22 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
WO2009067547A1 (en) * 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
WO2010083505A1 (en) 2009-01-19 2010-07-22 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
GB201205752D0 (en) 2012-03-30 2012-05-16 Cyclacel Ltd Treatment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014076994A (ja) * 2007-09-28 2014-05-01 Cyclacel Ltd プロテインキナーゼ阻害剤としてのピリミジン誘導体

Also Published As

Publication number Publication date
RU2013108456A (ru) 2014-09-10
HK1187895A1 (en) 2014-04-17
EP2610256B1 (en) 2016-04-27
RU2623221C2 (ru) 2017-06-23
JP5863196B2 (ja) 2016-02-16
RU2478100C2 (ru) 2013-03-27
US9493471B2 (en) 2016-11-15
CA2700979A1 (en) 2009-04-02
EP2610256A1 (en) 2013-07-03
PL2610256T3 (pl) 2016-11-30
CN101878216A (zh) 2010-11-03
RU2010116759A (ru) 2011-11-10
US20110046093A1 (en) 2011-02-24
WO2009040556A1 (en) 2009-04-02
US20140066436A1 (en) 2014-03-06
US9133199B2 (en) 2015-09-15
CA2700979C (en) 2017-06-20
CN101878216B (zh) 2013-07-10
EP2205603B1 (en) 2014-01-15
US20150344486A1 (en) 2015-12-03
US8563542B2 (en) 2013-10-22
PL2205603T3 (pl) 2014-07-31
JP2014076994A (ja) 2014-05-01
EP2205603A1 (en) 2010-07-14
ES2457394T3 (es) 2014-04-25
ES2585110T3 (es) 2016-10-03
HK1146042A1 (en) 2011-05-13
JP2010540509A (ja) 2010-12-24

Similar Documents

Publication Publication Date Title
JP5863196B2 (ja) プロテインキナーゼ阻害剤としてのピリミジン誘導体
AU2011217961B2 (en) Cyclobutane and methylcyclobutane derivatives as Janus kinase inhibitors
JP5043663B2 (ja) ジヒドロプテリジノン誘導体、その製造方法及び薬物としての使用
CA2458699C (en) Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
CA2656413C (en) Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals
JP5009155B2 (ja) 新規な６−ホルミル−テトラヒドロプテリジン、その製造方法および特に癌に対する医薬品としてのその使用
US20110053944A1 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
US20080108616A1 (en) Compounds and compositions as protein kinase inhibitors
JP2008510750A (ja) ジヒドロプテリジノン誘導体、その製造方法及び薬物としての使用
RU2671494C2 (ru) Некоторые ингибиторы протеинкиназы
EP1589967B1 (en) Benzthiazole-3 oxides useful for the treatment of proliferative disorders
US9233965B2 (en) 3,4-dihydropyrrolo[1,2-A]pyrazine-2,8(1H)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof for diseases involving casein kinase 1 epsilon and/or casein kinase 1 delta
HK1146042B (en) Pyrimidine derivatives as protein kinase inhibitors
HK1187895B (en) Pyrimidine derivatives as protein kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130909

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131106

R150 Certificate of patent or registration of utility model

Ref document number: 5410432

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250